Client Selection
Filter By
Priority Competitors
Pfizer
5 new alertsNovartis
3 new alertsRoche
2 new alertsAstraZeneca
1 new alertMerck
2 new alertsGSK
0 new alertsRecent Alerts
Multiple Myeloma
Pfizer granted priority review for new multiple myeloma therapy
The FDA has granted priority review for Pfizer's novel BCMA-targeted therapy for relapsed/refractory multiple myeloma. The PDUFA date is set for October 15, 2025.
Roche announces collaboration with biotech for novel multiple myeloma target
Roche has announced a strategic collaboration with a biotech company to develop a novel target for multiple myeloma. The deal includes $40M upfront.
Psoriatic Arthritis
Novartis reports positive Phase 3 results for IL-23 inhibitor in psoriatic arthritis
Novartis announced positive topline results from their Phase 3 trial of their IL-23 inhibitor in psoriatic arthritis. The study met its primary endpoint.
Treatment-Resistant Depression
Merck presents Phase 2 data for NMDA receptor modulator in treatment-resistant depression
Merck presented Phase 2 data for their novel NMDA receptor modulator in treatment-resistant depression at the American Psychiatric Association Annual Meeting.
Data Snacks
Multiple Myeloma
Multiple Myeloma Market Landscape
Analysis of the current multiple myeloma treatment landscape and emerging therapies, with focus on BCMA-targeted approaches.
CAR-T vs. Bispecific Antibodies in Multiple Myeloma
Comparative analysis of CAR-T cell therapies and bispecific antibodies in the treatment of multiple myeloma.
Psoriatic Arthritis
IL-23 vs. IL-17 Inhibitors in Psoriatic Arthritis
Comparative analysis of IL-23 and IL-17 inhibitors in the treatment of psoriatic arthritis, including efficacy and safety profiles.
Clinical Trial Updates from ClinicalTrials.gov
| Trial ID | Title | Sponsor | Disease State | Update Type | Date |
|---|---|---|---|---|---|
| NCT05123456 | Phase 3 Study of Novel Anti-BCMA Therapy in Multiple Myeloma | Pfizer | Multiple Myeloma | New Trial | May 28, 2025 |
| NCT04987654 | Study of IL-23 Inhibitor in Psoriatic Arthritis | Novartis | Psoriatic Arthritis | Status Change | May 27, 2025 |
| NCT05789012 | Phase 2 Study of NMDA Receptor Modulator in Treatment-Resistant Depression | Merck | Treatment-Resistant Depression | New Trial | May 25, 2025 |
Weekly Snapshot
May 22-28, 2025Key Alerts
12
+3 from last week
Clinical Trial Updates
8
+2 from last week
Publications
5
-1 from last week
New Alert
Pfizer granted priority review for new multiple myeloma therapy
The FDA has granted priority review for Pfizer's novel BCMA-targeted therapy for relapsed/refractory multiple myeloma.
© 2025 CI Agent. All rights reserved.